Last updated 2026-07-27
- Went public on NYSE American (PHGE), Aug 2019
- Acquired Zorronet, Apr 2026
- Acquired Dr. Frucht Systems , Apr 2026
Total raised
$187.3M
Last: Undisclosed Round 2025-03
Stage
Public
Founded
2015
Headcount
20
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
The company's platforms use computational and synthetic biology and research from Doctors Rotem Sorek, Eran Elinav, and Eran Segal of the Weizmann Institute of Science and Doctor Timothy K. Lu of the Massachusetts Institute of Technology.
With the establishment of X Security & Defense, BiomX intends to expand its presence in security and defense markets by identifying and commercializing technologies that address evolving operational needs across national security, emergency response, and critical infrastructure protection.
Funding history · 18 rounds · $187.3M total
2026-06
PIPE
$2.0M
2026-06
Follow-on PO
$5.1M
2026-02
Follow-on PO
Undisclosed
2025-12
PIPE
$3.0M
2025-04
Follow-on PO
$1.8M
2025-02
PIPE
$12.0M
2024-05
Follow-on PO
$12.0M
2023-06
Follow-on PO
$7.5M
2023-05
PIPE
$6.0M
2023-02
PIPE
$7.5M
2023-02
Follow-on PO
$1.5M
2022-04
Follow-on PO
$19.9M
2021-07
Follow-on PO
$15.0M
2019-10
Debt Financing
Undisclosed
2018-12
IPO
$70.0M
2017-11
Grant
Undisclosed
2017-04
A Round
$24.0M
★ OrbiMed★ Takeda Ventures★ Johnson & Johnson Innovation
2015-11
Seed
Undisclosed
★ FutuRx
Headcount over time
From 2 (2018-11) to 58 (2026-03) · +56 (+2800%) · 64 points · source: Finder history + radar grounding
Q&A
- What was the most recent funding round for BiomX?
- BiomX completed a PIPE funding round in February 2025, raising $12,000,000.
- What was the most recent acquisition made by BiomX?
- BiomX acquired Zorronet in April 2026.
- Who is the current CEO of BiomX?
- Michael Oster is the CEO of BiomX, appointed in March 2026.
- What is the primary focus of BiomX?
- BiomX is a clinical-stage biotechnology company developing natural and engineered phage therapies to target pathogenic bacteria underlying chronic and infectious diseases.
- What was the outcome of the Phase 2b BX004 trial for Cystic Fibrosis?
- In December 2025, BiomX announced the discontinuation of the Phase 2b BX004 trial following an internal review.
- What is the status of BiomX's BX211 program for Diabetic Foot Osteomyelitis (DFO)?
- In March 2025, BiomX announced positive topline results from the Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO).
- What is the status of BiomX's listing on the NYSE American?
- In June 2026, BiomX announced NYSE American's acceptance of its plan to regain compliance with listing standards.
- What is BiomX's involvement in the security and defense markets?
- In March 2026, BiomX launched a security subsidiary in Israel, intending to invest over $3 million in its operations to expand its presence in security and defense markets.
Team · 3
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Aerospace, Defense & HLSDefense & HLS SolutionsHealth Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceBiologicalsMicroorganisms
Target customers
Healthcare & Life SciencesLife SciencesCosmeticsPharmaceuticalsHealthcarePatients
Business model
B2B
Highlights
Verified
Tags
bioconvergencediabetesinflammatory-diseasescancertargeted-therapymicrobiologypharmaceuticalsmicrobiomebacteriaartificial-intelligencedrug-discoverygenomicsmachine-learningbiomarkersautoimmune-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biomx.com |
|---|---|
| linkedin.com/company/18049975 | |
| facebook.com/Biomx-2286421221606645 |
Identifiers & details
| Legal name | BiomX Inc. |
|---|---|
| Former names | MBcure |
| Founded | 2015-5 |
| Employees (exact) | 20 |
| Market cap | $2.9M |
| Status reason | registrar: בפרוק ע~י בימ~ש |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Zorronet | 2026-04 | |
| Dr. Frucht Systems | 2026-04 | |
| Adaptive Phage Therapeutics | 2024-03 | |
| RondinX | 2017-12 | — |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Public Offering | 2019-08 | NYSE American | PHGE |
Radar intelligence
Patents
| EPO | 8 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | biomx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 15 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515220556 |
|---|---|
| Status | בפרוק ע~י בימ~ש — CLOSED |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-03-03 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 7 — dissolution (1), charge (4), annual_report (2) |
| Closure date | 2026-01-28 |
| Registered address | אינשטיין 22 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-28 | פירוק ע~י בית משפט (חדלות פירעון) |
| 2026-02-26 | סילוק שעבוד |
| 2026-02-26 | סילוק שעבוד |
| 2026-02-26 | סילוק שעבוד |
| 2025-07-24 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-07-24 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2025-12-09 | סילוק שעבוד |